{
  "id": 13724122,
  "title": "Cytokinetics EVP Fady Malik sells $214,830 in company stock",
  "url": "https://urgent.news/2026/10/11/cytokinetics-evp-fady-malik-sells-214-830-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-11T13:16:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/cytokinetics-evp-fady-malik-sells-214830-in-company-stock-93CH-4942670"
  },
  "original_language": "en",
  "account": "Cytokinetics' Executive Vice President of Research & Development, Fady Malik, sold 3,500 shares of the company's common stock on October 6, 2026, for a total of $214,830. The shares were sold at $61.38 per share, slightly under the current price of $62.91. This transaction left Malik with a remaining holding of 153,902 shares. Analysts maintain a \"strong buy\" consensus for Cytokinetics, with price targets ranging from $85 to $146, despite the company's unprofitable status over the past year. On the same day, Malik also exercised non-qualified stock options, purchasing 3,500 shares at $7.8 per share, totaling $27,300. This brings his current non-qualified stock options to 19,886. Cytokinetics recently reported strong sales of its drug Myqorzo at $25.3 million for the second quarter, exceeding analyst estimates. The company has also filed a lawsuit against Bristol-Myers Squibb and MyoKardia over patent infringement concerns for MYQORZO.",
  "summary": null,
  "key_points": [
    "Fady Malik sold 3,500 shares at $61.38 per share",
    "Malik retained 153,902 shares after the sale",
    "Malik exercised 3,500 stock options for $27,300"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}